^
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
sorafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
lenvatinib
Sensitive
:
A1
NTRK1 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive
:
A2
TMB-H
Thyroid Gland Hurthle Cell Carcinoma
pembrolizumab
Sensitive
:
A2
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
denosumab
Sensitive
:
A2
RET fusion
Thyroid Gland Hurthle Cell Carcinoma
selpercatinib
Sensitive
:
A2
RET fusion
Thyroid Gland Hurthle Cell Carcinoma
pralsetinib
Sensitive
:
A2
NTRK3 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive
:
A2
NTRK3 fusion
Thyroid Gland Hurthle Cell Carcinoma
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Hurthle Cell Carcinoma
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Thyroid Gland Hurthle Cell Carcinoma
larotrectinib
Sensitive
:
A2
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our